Literature DB >> 18280703

Epilepsy and electroencephalographic anomalies in chromosome 2 aberrations. A review.

Salvatore Grosso1, Lucia Pucci, Paolo Curatolo, Giangennaro Coppola, Gabriella Bartalini, Rosanna Di Bartolo, Renato Scarinci, Alessandra Renieri, Paolo Balestri.   

Abstract

UNLABELLED: Epilepsy and electroencephalographic (EEG) anomalies are common in subjects carrying chromosomal aberrations. We report clinical and EEG investigations on 13 patients carrying chromosome 2 anomalies, including two patients with inversions, six with translocations, two with partial duplications and three with interstitial deletion syndromes. Epilepsy and/or EEG anomalies were found in one patient with a chromosome 2 translocation, in both of those carrying partial duplications and in all three with interstitial deletion syndromes. No epilepsy or EEG anomalies were detected in the remaining patients.
CONCLUSIONS: Epilepsy may be associated with chromosome 2 aberrations. Gross rearrangements involving the long arm of chromosome 2 might be more often associated with epilepsy than those involving the short arm. The association of epilepsy with chromosome 2 duplications is less clear. In particular, our observations and a review of the literature appear to suggest that a strict relationship between epilepsy and interstitial deletions involving the 2q24-q31 region. In the latter disorder tonic and focal seizures occur early in life. Generalized and focal myoclonic jerks tend to appear in infancy and are subsequently followed by seizures mixed in type. Seizures usually persist up to late childhood and are drug resistant. Further studies are necessary to better define the electroclinical patterns of patients carrying deletions in 2q24-q31. These may help to direct systematic study of this--probably underestimated--cause of severe epilepsy.

Entities:  

Mesh:

Year:  2008        PMID: 18280703     DOI: 10.1016/j.eplepsyres.2007.12.011

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  7 in total

1.  De novo SCN1A mutations in migrating partial seizures of infancy.

Authors:  D Carranza Rojo; L Hamiwka; J M McMahon; L M Dibbens; T Arsov; A Suls; T Stödberg; K Kelley; E Wirrell; B Appleton; M Mackay; J L Freeman; S C Yendle; S F Berkovic; T Bienvenu; P De Jonghe; D R Thorburn; J C Mulley; H C Mefford; I E Scheffer
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

2.  2q23.1 microdeletion identified by array comparative genomic hybridisation: an emerging phenotype with Angelman-like features?

Authors:  S Jaillard; C Dubourg; M Gérard-Blanluet; A Delahaye; L Pasquier; C Dupont; C Henry; A-C Tabet; J Lucas; A Aboura; V David; B Benzacken; S Odent; E Pipiras
Journal:  J Med Genet       Date:  2008-09-23       Impact factor: 6.318

Review 3.  Epilepsy and chromosomal abnormalities.

Authors:  Giovanni Sorge; Anna Sorge
Journal:  Ital J Pediatr       Date:  2010-05-03       Impact factor: 2.638

4.  Investigation of TBR1 Hemizygosity: Four Individuals with 2q24 Microdeletions.

Authors:  R N Traylor; W B Dobyns; J A Rosenfeld; P Wheeler; J E Spence; A M Bandholz; E V Bawle; E P Carmany; C M Powell; B Hudson; R A Schultz; L G Shaffer; B C Ballif
Journal:  Mol Syndromol       Date:  2012-08-23

5.  The human proteins MBD5 and MBD6 associate with heterochromatin but they do not bind methylated DNA.

Authors:  Sophie Laget; Michael Joulie; Florent Le Masson; Nobuhiro Sasai; Elisabeth Christians; Sriharsa Pradhan; Richard J Roberts; Pierre-Antoine Defossez
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

Review 6.  The ITGB6 gene: its role in experimental and clinical biology.

Authors:  Amelia Meecham; John F Marshall
Journal:  Gene X       Date:  2019-11-06

7.  The essential role of Mbd5 in the regulation of somatic growth and glucose homeostasis in mice.

Authors:  Yarui Du; Bo Liu; Fan Guo; Guifang Xu; Yuqiang Ding; Yong Liu; Xin Sun; Guoliang Xu
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.